2026年第一季度,制药巨头辉瑞公司宣布向其内部研发项目投入25亿美元资金。这笔巨额投资将主要用于推进创新药物管线开发,涵盖肿瘤学、疫苗研发及罕见病治疗等前沿领域。公司表示,此举旨在强化其长期科研实力,为未来业绩增长奠定坚实基础。
2026年第一季度,制药巨头辉瑞公司宣布向其内部研发项目投入25亿美元资金。这笔巨额投资将主要用于推进创新药物管线开发,涵盖肿瘤学、疫苗研发及罕见病治疗等前沿领域。公司表示,此举旨在强化其长期科研实力,为未来业绩增长奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.